AnCan thanks the following sponsors for making this recording possible: Bayer, Novartis, Johnson and Johnson, Myriad Genetics, Telix, Blue Earth Diagnostics and Foundation Medicine.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.
AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: Unpredictable & outstanding response to surgery for G4+5 man
Topics Discussed
Is Metastasis Directed Therapy right for me; G4+5 Gent has unpredictable & outstanding response to surgery; did his MSKCC GU MO really clock this Gent was taking abi w/o prednisone?; good response to ‘triplet’ post Pluvicto, but for how long then what next… alpha RLT?; is G4+5 hi-volume denovo Mx man ready for IHT after 18 months? what about debulking?; CARIS has good webinar on CHIP mutations; muscle pain from ADT; don’t just call, put it in your patient portal; Dr. Jack doesn’t favor ibuprofen
Chat Log
Bob McHugh sent: 3:37 PM
Curious to know who did the surgery … What about side effects, if I may ask? Please remind RD that there is no government work right nowL LOL
Steve – My respone is a bit complicated. If you’re interested, send me you email.
Julian – Houston sent: 4:00 PM
Need to leave early. Thanks again!!!
Steven T sent: 4:27 PM
Thanks everyone. Have a good night.
AnCan–John A sent: 4:36 PM
i have always been uncomfortable that RT wasn’t part of his treatment plan. I think he’s undertreated, though psa is .02. so I’m not happy about deintensifying
J. Ward sent: 4:42 PM
Need to leave early. Thanks, all!!
dan- no time needed tonight sent: 4:48 PM
Thanks all… another good session
AnCan – rick sent: 4:54 PM
Theraworx
Bruce Schrimpf sent: 5:03 PM
I will offer a prayer for Mr. Mason.
5Nice being with you all and thanks for the good imformation!
Hi-Risk/Recurrent/Advanced PrCa Video Chat, Aug 18, 2025
AnCan is grateful to the following sponsors for making this recording possible: Bayer, Novartis, Johnson and Johnson, Myriad Genetics, Telix, Blue Earth Diagnostics and Foundation Medicine
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Editor’s Pick: Confirm PSMA signs in esophagus are prostate cancer before starting hormone therapy (rd)
Topics Discussed
Active and healthy 85 yr old asks how to best manage recurrence; bladder neck involvement from surgery may complicate matters; Pluvicto in store fo foamy gland Gent; addressing neuropathy; waiting on test results to confirm small cell trial; anxiety is crippling; blood thinners may explain RT cystitis/proctitis; starting salvage RT; addressing osteoporosis during advanced treatment; RB mutation may invoke adtional chemo agent; check out PSMA signs in esophagus before starting HT for PrCa; following recurrence up to PSA of 1.0; holding a coupl eof Pluvicto sessions in reserve??
Thanks gents for another excellent group mtg… I have to check-out now.
Alain sent: 6:57 PM
I have to go guys, many thanks for a great meeting, I can present my update next time.
Gary V Portland, Oregon sent: 6:59 PM
Jeff thanks for all the suggestions these last 2+years .. You gave me the strength to fight to get Nubeqa and Orgovyx and you tied me up with AnCan.. you made a difference
Ed L sent: 7:11 PM
Thanks for the advice. Good night all time for bed.
Hi-Risk/Recurrent/Advanced PrCa Video Chat, July 21, 2025
MARKET RESEARCH STUDIES
AnCan has two new market research opportunities for you and your Care Partners with Pinpoint Patient Recruiting to earn up to $425.
Study #1
• Non-white Men &/or Carers – both can apply but with separate applications • Must be US based • Men confirmed hormone sensitive with or without mets OR castrate resistant • Active treatment is NOT required – you can be on a drug holiday
Study #2 – recruiting for survey in September • Men &/or Carers – both can apply but with separate applications • Must be US based • Men confirmed hormone sensitive with or without mets OR castrate resistant • Active treatment is NOT required – you can be on a drug holiday
$125 for a 60-minute virtual online interview with another $50 for providing evidence from your medical records of your confirmed diagnosis – screenshots suffice. If you opt in for a second interview, another $125 is available. Your Carers also have the opportunity to earn $125 for a 60 minute interview.
Please visit pinpointpatientrecruiting.com/pc-interview-ancan2025 or contact Brittany Weathersbee at brittany@pinpointpatientrecruiting.com. If you’ve already been contacted directly by Pinpoint from a prior study and accepted, please let us know at rd@ancan.org.
AnCan is grateful to the following sponsors for making this recording possible: Bayer, Novartis, Johnson and Johnson, Myriad Genetics, Telix, Blue Earth Diagnostics and Foundation Medicine
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Editor’s Pick: Pain meds should not be a pain! (rd)
Topics Discussed
Fatigue persists despite testosterone increasing and normal cortisol levels; advanced cancer spreads including to liver; using pain meds; identify the cancer before talking treatment and trials; Chuck Ryan gets NJ gold star for holding Gent off treatment; heart issues indicate apalutamide and more cardio follow up; 2x Pluvicto drives PSA down from 0.6 to 0.2 – consider holding treatments back; recurrence 3 mos post salvage RT requires GU MO’s opinion; Newwbie – triplet therapy brings PSA from 4900 to 6 – but GU MO required as QB.
Chia seeds are a complete protein Complete proteins are those that contain all nine essential amino acids. Essential amino acids are those that our bodies cannot create and must be obtained through food. These include histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine.
John A sent: 5:36 PM
nuts and seeds also for protein
gary peters sent: 5:55 PM
The FDA approved (1/25) a new non-opioid pain medication called suzetrigine, marketed as Journavx. This medication is designed to treat moderate-to-severe acute pain in adults by targeting pain signals in the peripheral nervous system, rather than acting on the brain like opioids.
kang sent: 5:55 PM
Lorigerlimab MacroGenics
Len Sierra sent: 5:57 PM
Lorigerlimab is an investigational, bispecific antibody targeting PD-1 and CTLA-4, designed to enhance immune checkpoint blockade in the tumor microenvironment.
Ben Nathanson sent: 5:59 PM
Gary, it’s approved for specific pain that may not be applicable to cancer patients: short-term moderate-to-severe acute pain (trauma or post-op) only —not chronic pain. But it’s an interesting new approach that’s likely to get plenty of company. The benefit is that you get pain relief plus alertness.
Mike sent: 6:02 PM
psa for years between 6-10, prostate biopsy 1.5 years ago negative, just received ExoDx urine test result =53. Any suggestions? Urologist recommends 25 core biopsy. Thanks
Hi-Risk/Recurrent/Advanced PrCa Video Chat, July 7, 2025
Hi-Risk/Recurrent/Advanced PrCa Video Chat, July 7, 2025
RECORD SETTER – 58 GENTS
AnCan is grateful to the following sponsors for making this recording possible: Bayer, Novartis, Johnson and Johnson, Myriad Genetics, Telix, Blue Earth Diagnostics and Foundation Medicine
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Editor’s Picks: Small cell morphing comes up twice in record setting group.(rd)
Topics Discussed
Hawaiian denovo Nx man finds Mack Roach; is the cancer morphing into small cell?; meta-study on early chemo not relevant if high PSA on Dx ; nevermind repeat PSMA – how about a PSA test?; another post-Pluvicto Gent whose cancer appears to morph; intraductal man is offered focal therapy – hello??; treatment success; UCSD team thinks suspicious local/distant Mx bogus – proceeds with simple RT; recurrence in Canada always poses treatment problems; zoledronic acid (Zometa) or denosumab (Xgeva) derivatives for osteoporosis?; does HT with salvage RT require abi?; Kwon’s doublet upgraded to triplet; what’s wrong with SoC options for man offered trials; another Mayo man needs GU MO Heath before proceeding.
Jeff Marchi – San Francisco sent: 6:29 PM Neuroendocrine trials From: MSKCC TargetDonc onclive ascopubs There are several ongoing clinical studies targeting DLL3 in neuroendocrine prostate cancer (NEPC): • Memorial Sloan Kettering Cancer Center (MSK) is opening a clinical trial testing a radioactive ligand that targets DLL3 in people with metastatic NEPC. Patients will first be screened for DLL3 expression and, if eligible, will receive the targeted therapy. • The SKYBRIDGE trial (NCT05652686) is a phase 1/2 study evaluating peluntamig (PT217), which targets DLL3 and CD47, in patients with DLL3-expressing neuroendocrine carcinomas, including NEPC. • A phase 1b study of tarlatamab, a DLL3-targeted bispecific T-cell engager, is ongoing in patients with metastatic NEPC, showing manageable safety and encouraging anti-tumor activity in DLL3-positive cases (NCT04702737). • Other agents like HPN328, another DLL3-targeted T-cell engager, are also being tested in neuroendocrine prostate cancer. These studies reflect a strong research focus on DLL3 as a therapeutic target for NEPC.
Alain sent: 7:16 PM Thanks guys, see you next time!
Doug D sent: 7:18 PM Thanks all. See you next time.
Wes – San Diego sent: 7:19 PM To all. Your great advice over the past 6 months helped me immensely in finding and getting great care, and a treatment plan that matched my goals.
George (Chicago) sent: 7:27 PM Thank you, gentlemen. Very helpful.
Bob Schwartz, USN, Venice FL sent: 7:35 PM Good mtg., got to go.
Thomas M sent: 7:37 PM Thank you all for your help. Thomas.
Jon McPhee Toronto sent: 7:37 PM Thanks. Goodnight.
Steve White sent: 7:44 PM Thanks so much for your help tonight. Goodnight.
Hi-Risk/Recurrent/Advanced PrCa Video Chat, June 16, 2025
AnCan is grateful to the following sponsors for making this recording possible: Bayer, Novartis, Johnson and Johnson, Myriad Genetics, Telix, Blue Earth Diagnostics and Foundation Medicine
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/
Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room
Editor’s Pick: After 20 years continuously on AS, 3+3 becomes metastatic (rd)
Topics Discussed
After 20 years continuously on AS, 3+3 becomes metastatic; man with recurrence must learn to be his own best advocate; denovo Mx Alaskan needs better treatment fromf the VA; success report from PBRT; trust Dr. Zhao!; primary treatment with BPH; long term management of recurrent, oligo-MX disease; abo vs daro; infections and A-fib defer PrCa Tx.; scans show clean but HT causes sweats and fatigue; youngr Gent shows nothing on PSMA at 0.14 – needs to switch his care; HT is doing its job
Chat Log
steve cavill – Melbourne, Australia sent: 5:32 PM what pirads? That gives a good idea of grade hmm ok, biopsy would be useful !
Bob Alvord sent: 6:02 PM I download all my scans, biopsy reports and labs to Chat Gtp. Chat returns detailed interpretations after I also mention that I am not a doctor, so in plain language. I also ask Chat for relevant questions. Not a perfect way but a good way to generate questions.
Jim Marshall, Alexandria, VA sent: 6:08 PM Veterans Support Group, Tuesday at 2000ET.
Jim Marshall, Alexandria, VA sent: 6:35 PM If one takes FINASTERIDE it will artifically drop the PSA by 50%.
Russ – PCaWarrior sent: 6:50 PM NCCN Low/favorable IR: SBRT alone is acceptable; ADT is optional. Unfavorable IR: SBRT + 4–6 months ADT is recommended. High risk: SBRT + 2–3 years ADT (Category 2A). Very high risk: SBRT only in trial settings; standard is EBRT ± brachytherapy + long‑term ADT. Finasteride : PSA. Finasteride blocks 5AR type 2. That is the predominant type in the prostate and PCa cells. DHT drops. PSA drops. Androgens (e.g. T) upgregulate PSA. ARSIs (e.g. Xtandi) downregulate it. Practical solution to upregulating or downregulating is to measure PSA in the same environment.
Jim Marshall, Alexandria, VA sent: 6:56 PM Was on Eligard + ABI for 5 years and NO SWEAT with side effects and now 3 years into Treatment Holiday and counting.. Mitigated ADT + ABI with exercise every day and diet.
Richard – Virginia sent: 7:04 PM i have to leave. I will talk next week.
dan, alexandria sent: 7:06 PM Thanks all… I have to leave.
Ben Nathanson sent: 7:36 PM John G –The first of these doesn’t seem to cite any sources, meaning none of the claims can be verified by readers. I distrust that. The second is in the context of chemotherapy, and is also retrospective — not clear it’s relevant to your case. Also fwiw the work was funded by Bayer, the maker of daro.
